RxDoctor Payments DataLook up a doctor →

Maria Padilla, MD

Pulmonary Disease · New York, NYNPI 1285652024

Payments from drug & device makers

$3,608,056in general payments, 2019–2025

Across 262 payments — averaging $13,771 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$3.1M
  • E.r. Squibb & Sons, L.L.C.$225K
  • Bristol Myers Squibb$61K
  • Cumberland Pharmaceuticals, Inc.$58K
  • Biogen$47K
  • GSK$37K
  • plus $54K from 9 others

What the payments were for

  • Consulting fees$53,87365%
  • Speaking & faculty fees$18,25422%
  • Grants$2,0002%
  • Travel & lodging$6,0517%
  • Food & beverage$2,8303%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,608,056 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$109,785
Medicare patients
290
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate179$2,384,916
Pirfenidone126$220,775
Trelegy ElliptaFluticasone/Umeclidin/Vilanter134$121,466
Breo ElliptaFluticasone/Vilanterol76$53,759
Spiriva RespimatTiotropium Bromide30$22,157
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$16,800
Mycophenolate Mofetil74$14,250
Incruse ElliptaUmeclidinium Bromide18$8,747
Qvar RedihalerBeclomethasone Dipropionate17$6,361
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$5,782
Advair HfaFluticasone Propion/Salmeterol12$4,597
Sildenafil Citrate11$4,261
Cevimeline Hcl25$4,111
Albuterol Sulfate HfaAlbuterol Sulfate61$1,582
Prednisone113$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$3,124,968$2,407,073209 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$36,950$200,773262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →